Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?
about
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece.Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis.Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 casesRisk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.Cytokines as biomarkers in depressive disorder: current standing and prospects.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09.
P2860
Q31158500-36E4A9EC-3B06-4384-AF70-7300B7A0F684Q34756501-E0A8826B-9CDB-415B-B7D9-AD89BB5CE9F9Q34944668-821C8802-68C7-4DCB-BD7D-DF9343AB5406Q36099620-BF31E03B-E19F-40FD-BB52-5C91FFF7715DQ36699795-18C9037F-5B37-4244-9546-59A83411D615Q37330765-FCD80BF9-14E2-4313-BDE6-1E1FACD64C72Q37729543-BBC712D5-DEEB-4169-9E4D-B68B6EF23CE6Q38154918-A153EC2C-E1B0-42A4-BD90-E538D272EAC1Q38192553-9C291AE2-E612-4EBC-9E9D-19BE60C630CEQ38827889-7AAF6904-3A86-4227-88E1-B9F0ADC4B3D6Q40553708-0118C2AC-22C3-417E-804F-6C988F22AF8DQ42240106-B0DE7DD1-BA5C-43D6-9CDD-8644A34CA9E1
P2860
Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Comparative safety of inflixim ...... ry by patient characteristics?
@ast
Comparative safety of inflixim ...... ry by patient characteristics?
@en
type
label
Comparative safety of inflixim ...... ry by patient characteristics?
@ast
Comparative safety of inflixim ...... ry by patient characteristics?
@en
prefLabel
Comparative safety of inflixim ...... ry by patient characteristics?
@ast
Comparative safety of inflixim ...... ry by patient characteristics?
@en
P2093
P2860
P356
P1476
Comparative safety of inflixim ...... ry by patient characteristics?
@en
P2093
Carlos G Grijalva
Elizabeth A Bayliss
Jeffrey R Curtis
Leslie R Harrold
Lingling Li
Lisa J Herrinton
Sengwee Toh
P2860
P304
P356
10.1002/PDS.3238
P577
2012-03-13T00:00:00Z